Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article reviews genetic and phenotypic aspects of androgen insensitivity syndromes, emphasizing the diversity of mutations that complicates molecular screening and the importance of genotype-phenotype correlations.

Alopecia areata has a high chance of persisting and relapsing, with a significant risk of total hair loss, especially if it starts in childhood.

In this case report, the authors describe a partial androgen insensitivity syndrome patient with a novel AR gene mutation, highlighting challenges in gender assignment decisions for infants with partial AIS.

This review, drawing on scientific literature, explores alopecia areata's pathogenesis and treatment, noting that while therapies like JAK inhibitors show promise, there remains a significant need for more effective and targeted solutions, and a better understanding of the disease mechanisms.

In this study, baricitinib was evaluated for its effectiveness in promoting concurrent regrowth of scalp hair, eyebrows, and eyelashes in patients with severe alopecia areata, showing clinically meaningful responses compared to placebo.

ATR04-484 ointment shows promise for treating skin issues from cancer therapies.

JAK inhibitors might help treat alopecia areata.

This narrative review found that ritlecitinib shows consistent effectiveness and a favorable safety profile for treating alopecia areata in clinical trials and real-world settings, with progressive hair regrowth observed, particularly when treatment is initiated early and maintained appropriately.

This document contains supplementary materials for a study on the efficacy and safety of a topical siRNA-based formulation targeting DKK-1 in androgenetic alopecia, but it reports no new findings.

This article reviews current and emerging treatments for alopecia areata, including Janus kinase inhibitors, highlighting variability in clinical outcomes and the lack of sustained remission.

In this study, researchers found that androgen receptor expression and AKR1C-mediated androgen inactivation, including AKR1C4, are prominent in scalp sebaceous glands, with AKR1C expression decreasing with age and differing by sex, suggesting these changes may impact hair follicle health as people age.

Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.

This case report discusses a 69-year-old woman with alopecia areata who presented with a growing lesion on her hand, raising diagnostic considerations during her appointment for scalp steroid injections.

This review discusses various potential treatments for alopecia areata, highlighting the promise of Janus kinase inhibitors but reports no new clinical results.

This study found that TAZ promotes adipogenesis in goat adipose-derived mesenchymal stem cells by enhancing PI3K/AKT pathway activity, with overexpression boosting adipocyte formation and knockdown inhibiting it.

This review of real-world treatment options for AA indicates that current therapies are insufficient, with high dissatisfaction rates, highlighting a need for improved solutions.

This study found that supplementing with 1.5% α-ketoglutaric acid significantly improved the performance, hair follicle density, and antioxidant capacity in Rex rabbits, potentially by enhancing the Wnt signaling pathway and reducing amino acid catabolism.

This systematic review concluded that oral JAK inhibitors, such as baricitinib and deuruxolitinib, are effective and generally well-tolerated treatments for moderate-to-severe alopecia areata, offering advantages over traditional therapies.

This study found a significant positive association between higher air quality index values and the incidence of alopecia areata, with a clear dose-response relationship observed among the participants.

This study found that NKIRAS2 expression affects skin tumor suppression and HRAS-driven transformation in mice, indicating its role in carcinogenesis depends on expression level and cellular context.

This retrospective study described the demographic characteristics, treatments, and prognosis of children with alopecia areata in a clinical setting, reporting a remission rate of 34.5% and highlighting the need for more comprehensive epidemiological data in this population.

This review discusses the role of JAK inhibitors in treating alopecia areata by targeting the JAK/STAT pathway and highlights the promising results but also ongoing challenges such as relapse risk and side effects.

The researchers reported that in a mouse model of alopecia areata, tofacitinib treatment influenced disease progression by modulating CD8⁺ T cell infiltration through the linoleic acid metabolism and magnesium ion pathway, offering insights into potential treatment approaches.

This study found that ritlecitinib was well tolerated in children aged 6 to under 12 years with severe alopecia areata, with ongoing trials examining its efficacy and safety over a 24-week period and in long-term use up to 36 months.

ALDOA levels drop in hair cells during hair loss.

This study found that oral JAK inhibitors are effective and generally well-tolerated for treating alopecia areata, but high recurrence rates after stopping treatment suggest the need for continuous use.

This study found that finasteride competitively inhibits the enzyme AKR1D1 with low micromolar affinity but does not act as a mechanism-based inactivator.

This study showed that androgenetic alopecia independently predicted higher mortality from diabetes and heart disease in both men and women, with increased rates in individuals with moderate or severe AGA.

This case study reports that an infant with maple syrup urine disease developed acrodermatitis dysmetabolica due to low isoleucine levels, and increasing the isoleucine dose improved the condition.

This study in the United Arab Emirates found that alopecia areata significantly impacts patient quality of life and healthcare resource utilization, particularly among those with higher scalp hair loss.